369 results on '"McAllister, Peter"'
Search Results
2. Correction: Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial
3. The temporal trend of placebo response in migraine prevention from 1990 to 2021: a systematic literature review and meta-analysis with regression
4. The critical role of affect regulation accounting for increased general distress, risk to self, and lower quality of life in females with EUPD and CPTSD, compared to EUPD alone
5. Cell Therapy for Chronic TBI: Interim Analysis of the Randomized Controlled STEMTRA Trial.
6. Inpatient Constipation Among Migraine Patients Prescribed Anti-calcitonin Gene-Related Peptide Monoclonal Antibodies and Standard of Care Antiepileptic Drugs: A Retrospective Cohort Study in a United States Electronic Health Record Database
7. Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial
8. EMERGE Study: An Open-label Evaluation of the Efficacy and Safety of AXS-07 (MoSEIC™ meloxicam-rizatriptan) for Migraine in Adults with Prior Inadequate Response to an Oral CGRP Inhibitor (P6-12.006)
9. Efficacy Remaining at Time of Requested Retreatment Following Botulinum Toxin Treatment for Cervical dystonia: Potential for a New Treatment Paradigm with DaxibotulinumtoxinA (P1-3.015)
10. Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study
11. Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial
12. Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies
13. Five-year prospective fistula audit in a single center. TIG training negates consultant learning curve, but surgeons should beware the mid-range palatal defect
14. Long‐term effectiveness of eptinezumab in the treatment of patients with chronic migraine and medication‐overuse headache.
15. Ethnic disparity in mental health legislation at the point of inpatient entry: pilot review in detained adolescents with developmental disorders
16. Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis
17. A genomic history of Aboriginal Australia
18. Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study
19. Impact of fremanezumab treatment on disability outcomes in patients with migraine and major depressive disorder: Results of the UNITE study
20. The critical role of affect regulation accounting for increased general distress, risk to self, and lower quality of life in females with EUPD and CPTSD, compared to EUPD alone
21. Benefit-risk assesment of atogepant: A post hoc anlysis of the advance trial
22. Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States
23. Safety and efficacy of sphenopalatine ganglion stimulation for chronic cluster headache: a double-blind, randomised controlled trial
24. A Novel Virtual-Based Comprehensive Clinical Approach to Headache Care
25. Metastasising Pleomorphic Salivary Adenoma: A Rare Case Report of a Massive Untreated Minor Salivary Gland Pleomorphic Adenoma with Concurrent Ipsilateral Cervical Node Metastases
26. Efficacy and Safety of AbobotulinumtoxinA (Dysport) for the Treatment of Hemiparesis in Adults With Upper Limb Spasticity Previously Treated With Botulinum Toxin: Subanalysis From a Phase 3 Randomized Controlled Trial
27. Long-term Safety of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia in Phase 3, Open-label, Multicenter ASPEN-OLS Trial (P11-11.003)
28. Benefit-Risk Assessment of Atogepant: A Post Hoc Analysis of the ADVANCE Trial (P12-12.001)
29. Transforming Music Teaching via Technology: The Role of Professional Development
30. Correction to: Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study
31. Factors Affecting University Music Students' Perceptions of Lesson Quality and Teaching Effectiveness
32. A TEACHER'S PERSPECTIVE ON WHAT'S WRONG WITH OUR SCHOOLS
33. Student Personality and Instrumental Participation, Continuation, and Choice
34. The Temporal Trend of Placebo Response in Migraine Prevention from 1990 to 2021: A Systematic Literature Review and Meta-Analysis with Regression
35. Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial
36. sj-pdf-3-cep-10.1177_03331024221128250 - Supplemental material for Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial
37. sj-pdf-4-cep-10.1177_03331024221128250 - Supplemental material for Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial
38. sj-pdf-6-cep-10.1177_03331024221128250 - Supplemental material for Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial
39. sj-pdf-2-cep-10.1177_03331024221128250 - Supplemental material for Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial
40. sj-pdf-5-cep-10.1177_03331024221128250 - Supplemental material for Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial
41. Early onset of efficacy with erenumab in patients with episodic and chronic migraine
42. Mitochondrial DNA diversity of present-day Aboriginal Australians and implications for human evolution in Oceania
43. A Cost-Effective, In-House, Positioning and Cutting Guide System for Orthognathic Surgery
44. The blood and the bone: The collection of human remains and frontier violence in colonial-era Queensland
45. Role of Calcitonin Gene-Related Peptide on the Gastrointestinal Symptoms of Migraine—Clinical Considerations: A Narrative Review
46. A Phase 3, Open-Label, Multicenter Trial to Evaluate the Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia
47. Efficacy and safety of abobotulinumtoxinA in spastic lower limb: Randomized trial and extension
48. Toxicology screening in oral and maxillofacial trauma patients
49. Rates of Response to Atogepant for Migraine Prophylaxis Among Adults
50. A Phase 3, Open-Label, Multi-Center Trial to Evaluate the Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults with Isolated Cervical Dystonia (P12-11.002)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.